As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

Samsung Bioepis released its Q1 2026 Biosimilar Market Report, which provides an overview of the market status of all ...

Ondibta is approved for the treatment of diabetes mellitus in adults, adolescents and in children aged two years old and ...

For companies developing interchangeable biosimilars, the FDA guidance opens the door to more tailored, risk-based programs that may reduce reliance on costly comparative efficacy studies (CES). For ...

Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.

An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy studies may prove ...

The letter was sent to Sens Cassidy, M.D. (R-La.) and Sanders (I-Vt.), chair and ranking member of the Senate Health ...

India’s Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha, ...

Please provide your email address to receive an email when new articles are posted on . Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co.), a HER2 receptor antagonist and biosimilar to ...

Nivolumab, launched at one-fourth the price of the original drug, is one of the most widely inhibitors used in treating various cancer types including lung, melanoma, kidney and Hodgkin lymphoma ...

Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market (B3) and a regional leader in hospital pharmaceuticals with a strong presence across Latin America, announces an ...